Microbix Biosystems (MBX) Q4 2025 earnings summary

Executive summary

• Fiscal year revenue declined 27% year-over-year, with $18.6 million reported and a net loss of $2.2 million, mainly due to the abrupt termination of a major client program and reduced demand for respiratory disease test ingredients.

• Excluding discontinued Kinlytic revenues and major client losses, recurring product sales and royalties grew in most categories, reflecting underlying business strength.

• Operational excellence was demonstrated through increased batch yields, reduced failure rates, and expanded capabilities, including recombinant antigen development.

• Management is focused on expanding product offerings and client base to recover revenue above breakeven and is positioned for recovery in fiscal 2026, with a robust business development pipeline and new product launches.

Financial highlights

• Total revenues declined 27% year-over-year, primarily due to the absence of CAD 4.1 million Kinlytic revenues and the loss of key client programs; full-year gross margin was 53%, down from 61% last year.

• Operating expenses increased by 4%, driven by higher R&D and trade show investments.

• Q4 revenue was $3.7 million, a 41% decrease year-over-year; Q4 net loss was $1.5 million versus net income of $0.4 million in Q4 2024.

• Cash and equivalents at year-end were over CAD 12 million ($12.1 million), with significant investments in capital equipment and facilities.

• Royalties increased in Q4 due to a stronger year for rabies vaccine technology, with accruals expected to rise in fiscal 2026.

Outlook and guidance

• Fiscal 2026 is expected to mark the beginning of recovery, with quarterly profitability targeted by Q4 and revenue growth of approximately 30% from the Q3 low point.

• Revenues for fiscal 2026 are projected to be substantially higher than CAD 14 million, based on signed contracts.

• Sufficient financial resources are available to fully execute current plans, with access to up to CAD 24 million in liquidity.

• No equity issuance is planned; share buybacks will continue, with a minimum budget of CAD 1 million for the coming year.

• Aggressive pursuit of new client programs and product expansion to drive sales growth and improve margins.